12.08.23 -- New Episodes: RNA Delivery Business, Gene Therapy Deals, Steve Gorlin's Golden Rules, and more.

Check out the latest episodes from Cell & Gene: The Podcast and Business of Biotech listed below. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

There’s nothing pretentious here. Just real, honest, transparent interactions with the leaders of emerging biotechs. Conversations about who they are, what they do, and why they do it. About what they’re building, what they’re tackling, and where they’re going from here. It only comes around once a month, but its contents are evergreen.

What constitutes a healthy, productive, and successful relationship between an emerging biopharma company and its CDMO? Jenny Holt, chief development officer at the biopharma company Ray Therapeutics has some opinions. So does John Maslowski, chief commercial officer at the CDMO Forge Biologics. Think they align?

Shortly after thalidomide became a household word — albeit a very, very bad one — a biotech investor bought it for a couple hundred grand. Who on earth would want a drug pulled from the market for causing birth defects? Steve Gorlin did.

Earlier this year, Shawn Davis, Ph.D., left a pretty comfortable position at AstraZeneca (and Amgen before that, and Milliken — and others — before that) to lead Liberate Bio. He brought along another industry notable in Merck/Intellia alumnus Walter Strapps, Ph.D., who serves as CSO at Liberate. Why'd they do it?

From his vantage point as an independent biotech journalist, Luke Timmerman has been watching the expansions and retractions of the industry for a couple of decades now. In this episode, we'll get to know Luke personally, learn about his philanthropic work, and give you a healthy dose of optimism as we look ahead to the next decade in biotech.

Partnerships, acquisitions, licensing agreements, and other deals with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of Regeneron's strategic partnerships making news this year. Nouhad Husseini, SVP and head of business development and corporate strategy at Regeneron is behind much of the dealmaking.

Hear from speakers on Cell & Gene: The Podcast about Meeting on the Mesa 2023, the event's new location for 2024, major topics and trends at this year's event, and ARM's GROW internship program.

What does the future of AAV gene therapy hold and how can you achieve scalability in manufacturing with consistent yield and product purity?

Astellas' Richard Wilson is Erin Harris's guest on Cell & Gene: The Podcast to discuss deals and collaborations in gene therapy.